Journey Medical Corporation 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K concerns actions taken at Journey Medical Corporation’s 2023 annual meeting of stockholders held on June 21, 2023. The report was signed and dated June 23, 2023. Journey Medical’s common stock trades on Nasdaq under the symbol DERM.
Key Financial and Operating Metrics
The filing does not report revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial performance metrics.
Material Changes and Corporate Actions
- Stockholders approved the 2023 Employee Stock Purchase Plan, which became effective upon approval. The plan was previously approved by the board in April 2023, subject to stockholder approval.
- Stockholders elected six directors: Lindsay A. Rosenwald, M.D.; Claude Maraoui; Neil Herskowitz; Dr. Jeffrey Paley; Justin Smith; and Miranda Toledano.
- Stockholders ratified KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2023.
Voting Results, Outlook, and Risks
Stockholders representing 12,377,569 shares, or 69.21% of the 17,881,528 shares entitled to vote, were represented at the meeting, constituting a quorum.
| Proposal | Result | Vote Summary |
|---|---|---|
| Election of six directors | Approved | Each director received between 16,015,287 and 16,158,703 votes for, with 53,399 to 196,815 votes withheld and 3,245,467 broker non-votes. |
| Ratification of KPMG LLP | Approved | 19,431,599 for; 25,051 against; 919 abstentions. |
| 2023 Employee Stock Purchase Plan | Approved | 16,085,316 for; 126,286 against; 500 abstentions; 3,245,467 broker non-votes. |
The filing provides no management guidance, financial outlook, material contingencies, or unusual financial items. The primary governance-related development is the effectiveness of the 2023 Employee Stock Purchase Plan.
Important Facts for Investors to Verify
- Review Exhibit 10.1 and the definitive proxy statement for the detailed terms, participation limits, purchase mechanics, and potential dilution under the 2023 Employee Stock Purchase Plan.
- Confirm the directors’ terms and committee assignments following the annual meeting.
- Review subsequent filings and the 2023 annual report for financial results, liquidity, debt, and any effects of employee stock purchases.
- Note that the filing states both 17,881,528 shares entitled to vote for quorum purposes and separate voting totals reflecting Class A common stock’s stated voting rights.